posted 5th January 2026
General Objectives
The aim of the National Haemoglobinopathy Panel (NHP) Cellular Therapy Group is to provide a national forum for discussion of specific transplant and cellular therapy (CT) issues for adult and paediatric patients approved by the NHP, or other commissioning eligibility, to proceed to hematopoietic stem cell transplantation (HSCT) and cellular therapies. This operational group aims to create harmonisation of protocols for adult and paediatric recipients, create a forum for data collection, case/outcomes reviews, and drive scientific research relating to stem cell transplant and cellular therapies. The Group is accountable to, and reports into the NHP.
The group is lead by the CTG Chair (Dr Kate Gardner) and a CRG lead/representative (Dr Subarna Chakravorty) as Co-Chairs, as well as 3 cohort leads covering adult sickle cell disorder (Dr Victoria Potter), adult thalassaemia (Dr Ben Carpenter), and paediatrics (Professor Josu de la Fuente).
CTG group meets once every month and attendees include other transplant/cellular therapy physicians, red cell clinicians, HCC clinical representatives and CNS representatives from all regions. All of whom are vital contributors to the workings of the CTG.
Patient Discussions
The CTG also discuss in-depth, cellular therapy focussed matters relating to specific patients who are either referred from the main NHP MDT in need of more CT focussed review, or patients currently undergoing CT who need input from specialist haemoglobinopathy transplant/CT experts. This is usually referred by the responsible transplant teams.
Download the referral form for direct NHP CTG patient case discussions.
